RT Journal Article
SR Electronic
T1 Increased extravascular lung water index (EVLWI) reflects rapid inflammatory oedema and mortality in COVID-19 associated ARDS
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.11.20192526
DO 10.1101/2020.09.11.20192526
A1 Sebastian Rasch
A1 Paul Schmidle
A1 Sengül Sancak
A1 Alexander Herner
A1 Christina Huberle
A1 Dominik Schulz
A1 Ulrich Mayr
A1 Jochen Schneider
A1 Christoph Spinner
A1 Fabian Geisler
A1 Roland M. Schmid
A1 Tobias Lahmer
A1 Wolfgang Huber
YR 2020
UL http://medrxiv.org/content/early/2020/09/11/2020.09.11.20192526.abstract
AB OBJECTIVE Nearly 5 % of the patients with COVID-19 develop an acute respiratory distress syndrome (ARDS). Extravascular lung water index (EVLWI) is a marker of pulmonary oedema which is associated with mortality in ARDS. In this study we evaluate whether EVLWI is higher in patients with COVID-19 associated ARDS as compared to controls and whether EVLWI has the potential to monitor disease progression.METHODS From the day of intubation, EVLWI, cardiac function were monitored by transpulmonary thermodilution in n=25 patients with COVID-19 and compared to a control group of 49 non-COVID-19 ARDS-patients.RESULTS EVLWI in COVID-19-patients was noticeably elevated and significantly higher than in the control group (17 (11-38) vs. 11 (6-26) mL/kg; p<0.001). High pulmonary vascular permeability index values (2.9 (1.0-5.2) versus 1.9 (1.0-5.2); p=0.003) suggest inflammatory oedema. By contrast, the cardiac parameters SVI, GEF and GEDVI were comparable. High EVLWI values were associated with viral persistence, prolonged intensive care treatment and mortality (23.2±6.7% vs. 30.3±6.0%, p=0.025).CONCLUSIONS Compared to the control group, COVID-19 results in markedly elevated EVLWI-values in patients with ARDS. EVLWI reflects a non-cardiogenic pulmonary oedema in COVID-19 associated ARDS and could serve as parameter to monitor ARDS progression.Competing Interest StatementTobias Lahmer received travel grants from Gilead, Pfizer and MSD. Sebastian Rasch received travel grants from Gilead. Christoph Spinner collaborates with AbbVie, Gilead, Janssen-Cilag, MSD and ViiV Healthcare/GSK as member of the advisory board and received travel and study grants. Wolfgang Huber collaborated with Pulsion Medical Systems SE, Feldkirchen, Germany as member of the Medical Advisory Board. All other authors declare that there is no conflict of interest.Clinical TrialISRCTN10077335Funding StatementNo external funding was obtained for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Technical University of Munich; Approval No. 178/20SAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data relevant for the analysis and conclusions of this study are included in this published article (and its Supplementary Information files). Exceeding information is available from the corresponding author on reasonable request.